SomaLogic, Inc. (SLGC): Price and Financial Metrics
SLGC Price/Volume Stats
|Current price||$2.34||52-week high||$3.79|
|Prev. close||$2.34||52-week low||$1.92|
|Day high||$2.38||Avg. volume||1,018,939|
|50-day MA||$2.19||Dividend yield||N/A|
|200-day MA||$2.61||Market Cap||440.09M|
SLGC Stock Price Chart Interactive Chart >
SLGC POWR Grades
- SLGC scores best on the Sentiment dimension, with a Sentiment rank ahead of 73.11% of US stocks.
- SLGC's strongest trending metric is Growth; it's been moving up over the last 177 days.
- SLGC's current lowest rank is in the Stability metric (where it is better than 12.04% of US stocks).
SLGC Stock Summary
- SLGC's went public 2.59 years ago, making it older than only 8.8% of listed US stocks we're tracking.
- The ratio of debt to operating expenses for SOMALOGIC INC is higher than it is for about just 0.33% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.14 for SOMALOGIC INC; that's greater than it is for only 10.91% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to SOMALOGIC INC are MXCT, SMRT, WISH, BASE, and PHR.
- To dig deeper into the stock's financial statements, go to SLGC's page on browse-edgar?action=getcompany&CIK=0001837412.
SLGC Valuation Summary
- SLGC's price/sales ratio is 4.2; this is 121.05% higher than that of the median Healthcare stock.
- SLGC's price/earnings ratio has moved up 2.9 over the prior 31 months.
Below are key valuation metrics over time for SLGC.
SomaLogic, Inc. (SLGC) Company Bio
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow-offrate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company's solutions also include SomaSignal tests, which are research use only tests for clinical trial applications. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions; and facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.
SLGC Latest News Stream
|Loading, please wait...|
SLGC Latest Social Stream
View Full SLGC Social Stream
Latest SLGC News From Around the Web
Below are the latest news stories about SOMALOGIC INC that investors may wish to consider to help them evaluate SLGC as an investment opportunity.
SomaLogic and Korea’s DNA Link partner to bring the 7,000-plex SomaScan® platform to the fast-growing Asia-Pacific proteomics market
DNA Link will bring the power of the largest proteomics platform available to their biomarker discovery and drug development workBOULDER, Colo. and SEOUL, Korea, Sept. 19, 2023 (GLOBE NEWSWIRE) -- SomaLogic Inc., (Nasdaq:SLGC), a leader in data-driven proteomics technology, today announced its partnership with DNA Link, an innovator in personalized and precision medicine, to offer the 7,000-plex SomaScan® platform to their customers. DNA Link will be the first SomaLogic authorized site in Korea.
SomaLogic researchers identify key proteins to aid in early detection of lung, colon and breast cancer and ovarian tumors
SomaLogic’s SomaScan® platform was used to target 15 markers shared among all cancer types.BOULDER, Colo., Sept. 12, 2023 (GLOBE NEWSWIRE) -- In a new paper published in Nature's Scientific Reports, researchers at SomaLogic Inc. studied the value of protein biomarkers in the early detection of cancer and the stratification of cancerous tumors. The research team identified 15 blood proteins shared among all cancer types as well as models to stratify tumor types. The goal of this research was to i
Novo Nordisk will extend its use of SomaLogic’s innovative proteomics technologies for research in cardiometabolic and other diseasesBOULDER, Colo., Sept. 05, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today that it is extending its collaborative agreement with global healthcare innovator, Novo Nordisk. As part of the agreement, which now extends into the end of 2025, Novo Nordisk will expand its use of the SomaScan® proteomics platform in drug researc
SomaLogic, Inc. ( NASDAQ:SLGC ) just released its quarterly report and things are looking bullish. Revenues and losses...
Revenue of $20.5 million, an increase of 45% year-over-yearCash and investments of approximately $474 million, a strong capital position to fund current and future business initiativesReiterating full year 2023 revenue guidance and operating expense targetManagement to host conference call today at 4:30pm ET BOULDER, Colo., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today reported financial results for the quarter ended June 30, 2023. “Our second quarte
SLGC Price Returns